Skip to main content
Clinical Trials/NCT05992623
NCT05992623CompletedNot Applicable

A Pragmatic Randomized Clinical Trial Comparing Rectilinear Biphasic Waveform and Biphasic Truncated Exponential Waveform Shocks for Cardioversion of Atrial Fibrillation (Zoll vs Lifepak)

Inova Health Care Services1 site in 1 country546 target enrollmentStarted: July 21, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
546
Locations
1
Primary Endpoint
The Number of Participants in Normal Sinus Rhythm (NSR) by ECG After the First DCCV Shock

Study Overview

Brief Summary

The goal of this single center, investigator initiated, open label prospective randomized controlled trial is to compare the efficacy of a single 200J RBW shock and a single 360J BTE shock. The secondary objective of the study is to compare the frequency of adverse events after one or two 200J RBW or 360J BTE shocks

Detailed Description

Data will be derived from approximately 560 patients arriving to Inova sites of care in Atrial Fibrillation (AF) scheduled to undergo either Atrial Fibrillation ablation with expected Direct Current Cardioversion (DCCV) or elective stand-alone AF DCCV. Patients will be included if they are in AF prior to their procedure and are willing to sign the information sheet and comply with the research procedures. Participants will be excluded if they are in a rhythm other than AF on arrival, have not been appropriately anticoagulated with warfarin or direct oral anticoagulant, or have known left atrial appendage thrombus prior to their procedure.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥ 18 years
  • •In AF on presentation with plan for DCCV in either the Electrophysiology lab or DCCV procedure area

Exclusion Criteria

  • •Participants who are receiving any other investigational agents.
  • •Parents/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
  • •Patients with arrhythmias other than AF
  • •Patients with hemodynamically unstable AF
  • •Patients with untreated hyperthyroidism
  • •Patients with known or suspected pregnancy
  • •Patients without sufficient anticoagulation or a transesophageal echocardiogram or computed tomography scan documenting the absence of intracardiac thrombi

Arms & Interventions

Output synchronized to 200J using Zoll Rectilinear Biphasic Waveform (RBW) defibrillator

Active Comparator

Participants receiving Direct Current Cardioversion (DCCV) using full output Rectilinear Biphasic Waveform (RBW) shocks from a Zoll defibrillator (200 Joules) up to 2 shocks.

Intervention: Zoll external defibrillator (Device)

Output synchronized to 360J Lifepak Biphasic Truncated Exponential Waveform (BTE) defibrillator

Active Comparator

Participants receiving Direct Current Cardioversion (DCCV) using full output Biphasic Truncated Exponential Waveform (BTE) shocks from a Physiocontrol/Medtronic Lifepak defibrillator (360 Joules) up to 2 shocks.

Intervention: Lifepak external defibrillator (Device)

Zoll defibrillator waveform used after unsuccessful second full output shock.

Active Comparator

Participants who received first shock via Zoll that do not have success after a second full output shock will be crossed over to the Lifepak defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.

Intervention: Lifepak external defibrillator (Device)

Lifepak defibrillator waveform used after unsuccessful second full output shock.

Active Comparator

Participants who received first shock via Lifepak that do not have success after a second full output shock will be crossed over to the Zoll defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.

Intervention: Zoll external defibrillator (Device)

Outcomes

Primary Outcomes

The Number of Participants in Normal Sinus Rhythm (NSR) by ECG After the First DCCV Shock

Time Frame: At least 1 minute after shock delivery

The frequency of NSR by ECG one minute after a single full output DCCV shock is delivered by either a 200J RBW waveform shock from a Zoll Series R defibrillator or 360J BTE waveform shock from a Lifepak 15 defibrillator

Secondary Outcomes

  • The Number of Participants in Normal Sinus Rhythm (NSR) by ECG After the First or Second DCCV Shock(At least 1 minute after shock delivery)
  • The Frequency of NSR One Minute After the First or Second Full Output DCCV Shock is Delivered by a Zoll Series R RBW Waveform Defibrillator and a Lifepak Series 15/20 BTE Waveform Defibrillator After Crossing Over From the Alternative Defibrillator.(At least 1 minute after shock delivery)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials